Article
Cell Biology
Mihoko Yoshino, Jun Yoshino, Gordon I. Smith, Richard I. Stein, Adam J. Bittel, Daniel C. Bittel, Dominic N. Reeds, David R. Sinacore, W. Todd Cade, Bruce W. Patterson, Kevin Cho, Gary J. Patti, Bettina Mittendorfer, Samuel Klein
Summary: The study found that intensive lifestyle therapy provided at the worksite has profound therapeutic clinical and physiological effects in people with T2D, which are likely mediated by specific alterations in skeletal muscle and adipose tissue biology.
Article
Chemistry, Medicinal
Saeid Hadi, Reza Daryabeygi-Khotbehsara, Parvin Mirmiran, Jenna McVicar, Vahid Hadi, Davood Soleimani, Gholamreza Askari
Summary: The study demonstrated that Nigella sativa oil extract had beneficial effects on glycemic control, serum lipid profile, blood pressure, and body weight among people with type 2 diabetes. Further long-term trials are needed to confirm the therapeutic benefits of Nigella sativa in T2D.
PHYTOTHERAPY RESEARCH
(2021)
Article
Multidisciplinary Sciences
Yasuhiro Watanabe, Daisuke Suzuki, Nobuichi Kuribayashi, Daigaku Uchida, Mitsutoshi Kato, Hiroshi Ohashi, Daiji Nagayama, Takashi Yamaguchi, Masahiro Ohira, Atsuhito Saiki, Ichiro Tatsuno
Summary: In patients with type 2 diabetes treated with dapagliflozin, a protein-enriched diet does not contribute to HbA1c reduction, but can decrease serum insulin and body fat mass, as well as increase HDL-cholesterol compared to a fat-enriched diet with identical calorie and carbohydrate ratios.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Charlotte K. Boughton, Afroditi Tripyla, Sara Hartnell, Aideen Daly, David Herzig, Malgorzata E. Wilinska, Cecilia Czerlau, Andrew Fry, Lia Bally, Roman Hovorka
Summary: In this study, fully closed-loop insulin therapy was found to improve glucose control and reduce hypoglycemia compared to standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis. The trial demonstrated increased time in target glucose range and decreased risk of hypoglycemia in patients with type 2 diabetes who require dialysis.
Review
Pharmacology & Pharmacy
Yan Tang, Lin Zhang, Yuping Zeng, Xia Wang, Mei Zhang
Summary: This systematic review and meta-analysis evaluated the clinical efficacy and safety of tirzepatide in patients with type 2 diabetes. The results showed that tirzepatide significantly reduced HbA1c, fasting serum glucose, and body weight, and improved blood pressure and fasting lipid profiles without increasing the risk of hypoglycemia.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Chi-Ho Lee, Mei-Zhen Wu, David Tak-Wai Lui, Darren Shing-Hei Chan, Carol Ho-Yi Fong, Sammy Wing-Ming Shiu, Ying Wong, Alan Chun-Hong Lee, Joanne King-Yan Lam, Yu-Cho Woo, Karen Siu-Ling Lam, Kelvin Kai-Hang Yiu, Kathryn Choon-Beng Tan
Summary: In insulin-treated T2DM patients with long diabetes duration, dapagliflozin significantly increased serum BHB levels compared to sitagliptin, and was associated with cardiometabolic improvements.
DIABETES & METABOLISM JOURNAL
(2022)
Review
Medicine, General & Internal
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R. Webb, Melanie J. Davies
Summary: Type 2 diabetes accounts for nearly 90% of global diabetes cases, with an increasing number of affected individuals, particularly among young people. Early detection and proactive management are crucial for preventing complications and reducing mortality. Technology and precision medicine offer potential improvements to treatment outcomes but face significant barriers.
Article
Endocrinology & Metabolism
Hsin-Ju Chen, Wei-Hsin Huang, Hsin-Lung Chan, Lee-Ching Hwang
Summary: The study demonstrates that smoking cessation can improve glycemic control and cardiometabolic risk factors in patients with type 2 diabetes, including reducing blood pressure and lipid levels; younger participants and higher nicotine dependence scores are associated with better decreases in blood sugar and total cholesterol levels; participation in the smoking cessation program is associated with improvements, but not with the decrease in smoking amount.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY
(2021)
Article
Endocrinology & Metabolism
Wenjing Ye, Lijuan Xu, Yanbin Ye, Fangfang Zeng, Xin Lu, Yanbing Li, Liehua Liu
Summary: This meta-analysis evaluated the efficacy and safety of meal replacement (MR) in type 2 diabetes (T2D) patients, with focus on subgroup analysis. Results showed that MR significantly improved glycemic control and adipose indicators in T2D patients. Total MR and MR with caloric restriction were more effective, regardless of insulin treatment.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Niala den Braber, Miriam M. R. Vollenbroek-Hutten, Kathryn M. Westerik, Stephan J. L. Bakker, Gerjan Navis, Bert-Jan F. van Beijnum, Gozewijn D. Laverman
Summary: In insulin-treated patients with type 2 diabetes, high HbA(1c) did not decrease the occurrence of nocturnal hypoglycemia, and low HbA(1c) was not associated with the highest time in range (TIR). Optimal personalization of glycemic control requires the use of newer tools, including CGM-derived parameters.
Article
Medicine, General & Internal
Ildiko Lingvay, Marisse Asong, Cyrus Desouza, Pierre Gourdy, Soumitra Kar, Andre Vianna, Tina Vilsboll, Siri Vinther, Yiming Mu
Summary: Once-weekly insulin icodec may serve as a simpler alternative to daily basal insulin for patients with type 2 diabetes. In this study, once-weekly icodec demonstrated superior reduction in HbA1c compared to once-daily degludec after 26 weeks of treatment in insulin-naive type 2 diabetes patients, with no difference in weight change but a slightly higher rate of combined level 2 or 3 hypoglycemic events.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, General & Internal
Ildiko Lingvay, Marisse Asong, Cyrus Desouza, Pierre Gourdy, Soumitra Kar, Andre Vianna, Tina Vilsboll, Siri Vinther, Yiming Mu
Summary: Once-weekly insulin icodec could be a simpler dosing alternative to daily basal insulin for type 2 diabetes patients. The study compared the efficacy and safety of once-weekly icodec with once-daily insulin degludec and found that icodec was superior in reducing HbA1c levels after 26 weeks, with no difference in weight change but a slightly higher rate of hypoglycemic events in the icodec group.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Multidisciplinary Sciences
Carolina Lopez-Cano, Maria Dolores Santos, Enric Sanchez, Raquel Marti, Marta Bueno, Liliana Gutierrez-Carrasquilla, Albert Lecube
Summary: The combination therapy of exenatide and dapagliflozin appears to be a strategic option for reducing the waiting list for bariatric surgery and achieving weight loss and BMI reduction in patients with type 2 diabetes.
SCIENTIFIC REPORTS
(2022)
Article
Endocrinology & Metabolism
Rena Pollack, Itamar Raz, Stephen D. Wiviott, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Ofri Mosenzon, Anna Maria Langkilde, Ingrid A. M. Gause-Nilsson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P. H. Wilding, Marc S. Sabatine, Avivit Cahn
Summary: This study explored the cardiorenal benefits of adding SGLT2 inhibitor therapy for patients on insulin. The results showed that dapagliflozin reduced cardiovascular and renal risks and had no significant impact on insulin dose and regimen.
Article
Endocrinology & Metabolism
Natalia McInnes, Stephanie Hall, Irene Hramiak, Ronald J. Sigal, Ronald Goldenberg, Nikhil Gupta, Remi Rabasa-Lhoret, Manoela Braga, Vincent Woo, Farah Sultan, Rose Otto, Ada Smith, Diana Sherifali, Yan Yun Liu, Hertzel C. Gerstein
Summary: The study aimed to evaluate the remission of type 2 diabetes after a short-term intervention using insulin glargine, sitagliptin/metformin, and lifestyle approaches. The results showed that although the primary outcome was not statistically significant, the intervention group had a lower risk of relapse and a higher number of participants remaining in remission in some supplementary analyses.